The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management
Open accessAbstract
Polycystic liver disease (PLD) is the result of embryonic ductal plate malformation of the intrahepatic biliary tree. The phenotype consists of numerous cysts spread throughout the liver parenchyma. Cystic bile duct malformations originating from the peripheral biliary tree are called Von Meyenburg complexes (VMC). In these patients embryonic remnants develop into small hepatic cysts and usually remain silent during life. Symptomatic PLD occurs mainly in the context of isolated polycystic liver disease (PCLD) and autosomal dominant polycystic kidney disease (ADPKD). In advanced stages, PCLD and ADPKD patients have massively enlarged livers which cause a spectrum of clinical features and complications. Major complaints include abdominal pain, abdominal distension and atypical symptoms because of voluminous cysts resulting in compression of adjacent tissue or failure of the affected organ. Renal failure due to polycystic kidneys and non-renal extra-hepatic features are common in ADPKD in contrast to VMC and PCLD. In general, liver function remains prolonged preserved in PLD. Ultrasonography is the first instrument to assess liver phenotype. Indeed, PCLD and ADPKD diagnostic criteria rely on detection of hepatorenal cystogenesis, and secondly a positive family history compatible with an autosomal dominant inheritance pattern. Ambiguous imaging or screening may be assisted by genetic counseling and molecular diagnostics. Screening mutations of the genes causing PCLD (PRKCSH and SEC63) or ADPKD (PKD1 and PKD2) confirm the clinical diagnosis. Genetic studies showed that accumulation of somatic hits in cyst epithelium determine the rate-limiting step for cyst formation. Management of adult PLD is based on liver phenotype, severity of clinical features and quality of life. Conservative treatment is recommended for the majority of PLD patients. The primary aim is to halt cyst growth to allow abdominal decompression and ameliorate symptoms. Invasive procedures are required in a selective patient group with advanced PCLD, ADPKD or liver failure. Pharmacological therapy by somatostatin analogues lead to beneficial outcome of PLD in terms of symptom relief and liver volume reduction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Autosomal dominant polycystic kidney disease
Torres, V. E., Harris, P. C., & Pirson, Y. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60601-1 · Cited by 1,550
Mutations in PRKCSH cause isolated autosomal dominant polycystic liver disease
Li, A., Davila, S., Furu, L., Qian, Q., Tian, X., Kamath, P. S., King, B. F., Torres, V. E., & Somlo, S. (2003) · The American Journal of Human Genetics · doi:10.1086/368295 · Cited by 193 · cited 1×
“Genetic analyses of both PCLD genes PRKCSH [OMIM*177060] and SEC63 [OMIM*608648] may confirm the clinical diagnosis and differentiate it from other PLD (Table 1) [56-58].”
BackgroundVan Keimpema, L., De Koning, D. B., Van Hoek, B., Van Den Berg, A. P., Van Oijen, M. G. H., De Man, R. A., Nevens, F., & Drenth, J. P. H. (2011) · Liver International · doi:10.1111/j.1478-3231.2010.02247.x · Cited by 152 · cited 10×
“There is no clear genotype-phenotype association [15,61].”
BackgroundInfluentialSelf-citationExtensive mutational analysis ofPRKCSH andSEC63 broadens the spectrum of polycystic liver disease
Waanders, E., te Morsche, R. H. M., de Man, R. A., Jansen, J. B. M. J., & Drenth, J. P. H. (2006) · Human Mutation · doi:10.1002/humu.9441 · Cited by 64 · cited 2×
“Clinical asymptomatic or undiagnosed members contribute to underestimation of the actual disease prevalence [24,41,61].”
Background
Cited by
Bergmann, C., Guay-Woodford, L. M., Harris, P. C., Horie, S., Peters, D. J. M., & Torres, V. E. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0047-y · Cited by 807
Autosomal dominant polycystic kidney disease
Cornec-Le Gall, E., Alam, A., & Perrone, R. D. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32782-x · Cited by 624
Porath, B., Gainullin, V. G., Cornec-Le Gall, E., Dillinger, E. K., Heyer, C. M., Hopp, K., Edwards, M. E., Madsen, C. D., Mauritz, S. R., Banks, C. J., et al. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2016.05.004 · Cited by 475
Genetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases
Cornec-Le Gall, E., Torres, V. E., & Harris, P. C. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017050483 · Cited by 406
Michelotti, G. A., Tucker, A., Swiderska-Syn, M., Machado, M. V., Choi, S. S., Kruger, L., Soderblom, E., Thompson, J. W., Mayer-Salman, M., Himburg, H. A., et al. (2016) · Gut · doi:10.1136/gutjnl-2014-308176 · Cited by 40
Metadata
- Authors
- Cnossen, W. R., & Drenth, J. P.
- Venue
- Orphanet Journal of Rare Diseases
- Published
- 2014
- Volume
- 9
- Issue
- 1
- Pages
- 69
- ISSN
- 1750-1172 (ISSN-L)
- OpenAlex
- W2163561265
- Cited by
- 200
- References
- 4
- FWCI
- 8.52
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management. https://app.cochat.ai/papers/10.1186/1750-1172-9-69
- The paper
- Cnossen, W. R., & Drenth, J. P. (2014). Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management. Orphanet Journal of Rare Diseases. https://doi.org/10.1186/1750-1172-9-69
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.